Arctic Bioscience – Board approval of share capital increase related to conversion of debt
Reference is made to the stock exchange release published by Arctic Bioscience 9th December 2025 regarding exercise of right to convert debt and corresponding issuance of new shares in Arctic Bioscience.
On 12 December 2025, the Board of Arctic Bioscience, on the basis of a board authorization granted by the Company’s General Meeting on 26th May 2025, resolved to increase the share capital from NOK 2 685 934 to NOK 2 695 625,60 by issuance of 96 916 new shares with a nominal value of NOK 0,10 per share, at a subscription price of NOK 2,789659405 per share, including a share premium of NOK 2,689659405 per share.
The total amount allocated as share premium is NOK 260 671,03. The total subscription amount is NOK 270 362,63. Following the registration of this share capital increase in the Norwegian Register of Business Enterprises, the Company’s share capital will be NOK 2 695 625,60 divided into 26 956 256 shares, each having a nominal value of NOK 0,10.
Minutes from Board Meeting and statement regarding capital increase are attached hereto.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Act.